Indolent course of thymic carcinoid.

J Clin Oncol

University of Louisville, J.G. Brown Cancer Center, Louisville, KY, USA.

Published: March 2007

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2006.09.8855DOI Listing

Publication Analysis

Top Keywords

indolent course
4
course thymic
4
thymic carcinoid
4
indolent
1
thymic
1
carcinoid
1

Similar Publications

Borderline ovarian tumors (BOTs) are rare in pediatric populations and typically follow an indolent clinical course with few reported recurrences. Consequently, guidelines for pediatric BOT management are minimal. We retrospectively examined the management of 15 adolescent patients who underwent BOT resection at our institution over 14 years, with a specific focus on recurrence.

View Article and Find Full Text PDF

spp. rarely cause infection in humans and are most common in the immunocompromised population. Pulmonary nocardiosis is the most common presentation.

View Article and Find Full Text PDF

Follicular lymphoma (FL) represents the second most frequent type of non-Hodgkin lymphoma and the most common indolent histology. The disease course of FL is heterogeneous, likely resulting from diverse molecular and immunological features that drive a broad spectrum of clinical presentations. While some patients with low-volume and asymptomatic disease are suitable for observation, patients with high tumor burden, advanced-stage, or symptomatic disease more often necessitate treatment initiation.

View Article and Find Full Text PDF

Small intestinal neuroendocrine tumors (SI-NETs) typically follow an indolent disease course and are often accompanied by mesenteric lymph node metastases upon diagnosis. These tumors can incite a fibroblastic reaction within the mesenteric root. Here, we present two cases of patients with symptomatic small bowel obstruction due to such mesenteric involvement.

View Article and Find Full Text PDF

Nodular lymphocyte-predominant Hodgkin lymphoma revisited: current management strategies and future perspectives.

Leuk Lymphoma

January 2025

First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Cologne, Germany.

Article Synopsis
  • Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare type of lymphoma, making up about 5% of Hodgkin lymphoma cases, and shares some characteristics with B-cell non-Hodgkin lymphoma.
  • NLPHL is typically diagnosed at early stages and has a slow progression, leading to excellent long-term survival rates for most patients.
  • Treatment mainly mirrors classical Hodgkin lymphoma but may include rituximab; future strategies could involve innovative therapies like CAR T-cell therapy and bispecific antibodies.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!